AIMI Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to AIM ImmunoTech's net margin of --. AIM ImmunoTech's return on equity of -- beat Perspective Therapeutics's return on equity of --.

AIM ImmunoTech has a consensus price target of $1.50, signalling upside risk potential of 2105.88%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 492.3%. Given that AIM ImmunoTech has higher upside potential than Perspective Therapeutics, analysts believe AIM ImmunoTech is more attractive than Perspective Therapeutics.

AIM ImmunoTech has a beta of 0.760, which suggesting that the stock is 23.953% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. AIM ImmunoTech's net income of -- is lower than Perspective Therapeutics's net income of -$40.2M. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 22.40x versus 15.73x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to AIM ImmunoTech's net margin of 12.11%. AIM ImmunoTech's return on equity of -- beat Electromed's return on equity of 15.91%.

AIM ImmunoTech has a consensus price target of $1.50, signalling upside risk potential of 2105.88%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 60.31%. Given that AIM ImmunoTech has higher upside potential than Electromed, analysts believe AIM ImmunoTech is more attractive than Electromed.

AIM ImmunoTech has a beta of 0.760, which suggesting that the stock is 23.953% less volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. AIM ImmunoTech's net income of -- is lower than Electromed's net income of $2M. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Electromed's PE ratio is 30.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 22.40x versus 3.47x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to AIM ImmunoTech's net margin of 35.65%. AIM ImmunoTech's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

AIM ImmunoTech has a consensus price target of $1.50, signalling upside risk potential of 2105.88%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 393.2%. Given that AIM ImmunoTech has higher upside potential than Protalix BioTherapeutics, analysts believe AIM ImmunoTech is more attractive than Protalix BioTherapeutics.

AIM ImmunoTech has a beta of 0.760, which suggesting that the stock is 23.953% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. AIM ImmunoTech's net income of -- is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 98.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 22.40x versus 4.57x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to AIM ImmunoTech's net margin of -10.04%. AIM ImmunoTech's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

AIM ImmunoTech has a consensus price target of $1.50, signalling upside risk potential of 2105.88%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that AIM ImmunoTech has higher upside potential than Xtant Medical Holdings, analysts believe AIM ImmunoTech is more attractive than Xtant Medical Holdings.

AIM ImmunoTech has a beta of 0.760, which suggesting that the stock is 23.953% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. AIM ImmunoTech's net income of -- is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 22.40x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.